The Oncotyrol Prostate Cancer Outcome and Policy Model - How Latent Prevalence Affects the Benefit-Harm Balance of Screening.
Mühlberger N, Heijnsdijk EA, Kurzthaler C, Iskandar R, Krahn MD, Bremner K, Oberaigner W, Klocker H, Horninger W, Conrads-Frank A, Sroczynski G, Siebert U.
Mühlberger N, et al. Among authors: oberaigner w.
Value Health. 2014 Nov;17(7):A559. doi: 10.1016/j.jval.2014.08.1843. Epub 2014 Oct 26.
Value Health. 2014.
PMID: 27201843
Free article.
No abstract available.